

ADVANCE Praise

Sometimes an artfully crafted quasi-acronym can help distinguish one otherwise indistinguishable clinical advance from another (1–3). The infectiousness of this engaging wordplay is evidenced by a recent report describing the role of Tirofiban for prevention of ischemic complications among high-risk patients undergoing coronary angioplasty (4)—a distinguished advance indeed!

*George A. Diamond, MD, FACC

*2408 Wild Oak Drive
Los Angeles, CA 90068
E-mail: gadiamond@pol.net

doi:10.1016/j.jacc.2004.11.012

REFERENCES

1. The ADVANCE Investigators. Rationale and design of the ADVANCE study: a randomized trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. *Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation*. *J Hypertens Suppl* 2001;19 Suppl 4:S21–8.
2. Serruys PW, Foley DP, Suttorp MJ, et al. A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions: final results of the additional value of NIR stents for treatment of long coronary lesions (ADVANCE) study. *J Am Coll Cardiol* 2002;39:393–9.
3. Russell SD, Selaru P, Pyne DA, et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin Antagonist in CHF patients undergoing Exercise) trial. *Am Heart J* 2003;145:179–86.
4. Valgimigli M, Percoco GF, Barbieri D, et al. The additive value of tirofiban administered with the high dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty (ADVANCE) trial. *J Am Coll Cardiol* 2004;44:14–9.

REPLY

We thank Dr. Diamond for his interest in our recent paper (1).

It can happen that, when a trial is designed, not enough attention is paid to the (quasi)-acronym used to identify the study. Unfortunately, it also happens that the medical world finishes paying more attention to it than to the trial message itself, and that is not a distinguished advance indeed! But the lesson is clear: from now on, we will keep ADVANC(E)ing with new STRATEG(Y)ies (2).

*Marco Valgimigli, MD
Patrick W. Serruys, MD, PhD, FACC

*University of Ferrara
Cardiovascular Institute
Arcispedale S. Anna Hospital
Corso Giovecca 203
44100 Ferrara
Italy
E-mail: vlgmrc@unife.it

doi:10.1016/j.jacc.2004.11.013

REFERENCES

1. Valgimigli M, Percoco G, Barberi D, et al. The additive value of tirofiban administered with the high dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty (ADVANCE) trial. *J Am Coll Cardiol* 2004;44:14–9.
2. Valgimigli M, Percoco GF, Cicchitelli G, et al. High dose bolus Tirofiban and sirolimus eluting stent versus abciximab and bare metal stent in acute myocardial infarction (STRATEGY) study—protocol design and demography of the first 100 patients. *Cardiovasc Drugs Ther* 2004;18:225–30.

CORRECTION

Chessa M, Butera G, Carminati M. Letter to the Editor: Risk of Thrombus Formation on Devices Used to Close Transcatheter Atrial Septal Defect and Patent Foramen Ovale. *J Am Coll Cardiol* 2004;44:1712.

The correct authors' names are Massimo Chessa, MD, PhD, Gianfranco Butera, MD, PhD, and Mario Carminati, MD.

doi:10.1016/j.jacc.2004.12.033